Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is Thymosin Alpha-1?
Thymosin Alpha-1 (TA-1) is a 28-amino acid peptide naturally produced by the thymus gland. It was isolated from thymosin fraction 5 (a thymic extract) by Allan Goldstein's laboratory at George Washington University in the 1970s. The synthetic version, manufactured by SciClone Pharmaceuticals as Zadaxin, has become one of the most internationally approved immune-modulating drugs in the world — despite never receiving FDA or EMA approval.
TA-1 is the active component of the thymic hormone responsible for T-lymphocyte maturation and immune surveillance. It has been approved in more than 35 countries for chronic hepatitis B, hepatitis C (as an adjuvant to interferon), and as a general immune adjuvant for various infections and cancers.
The Aging Immune System Rationale
The longevity interest in TA-1 stems directly from a fundamental feature of aging biology:
- Thymic involution: The thymus gland begins shrinking after puberty and is largely replaced by fat tissue by age 60–70. This progressive involution dramatically reduces the output of new naïve T-cells
- Consequence: Reduced naïve T-cell output means the immune system relies increasingly on memory T-cells, losing the ability to recognize novel pathogens and aberrant cancer cells
- Immunosenescence: The overall decline in immune competence with age — increased susceptibility to infections, reduced vaccine response, increased cancer risk
- TA-1's role: May partially compensate for reduced thymic output by promoting maturation and function of residual T-cell precursors through non-thymic pathways
Mechanism of Action
- Dendritic cell maturation: Promotes differentiation and activation of dendritic cells — the antigen-presenting cells that initiate adaptive immune responses
- Th1 polarization: Drives T-cell differentiation toward Th1 (cellular immunity) phenotype, critical for antiviral and anti-tumor immunity
- NK cell activation: Increases natural killer cell activity — important for innate immune surveillance
- Cytokine upregulation: Increases IL-2 and IFN-γ production — key effector cytokines for cellular immunity
- Regulatory balance: Reduces excessive Th2 and inflammatory responses — the immunomodulatory (not immunostimulatory) character of TA-1
Approved Indications by Region
| Region/Country | Approved Indication | Brand Name |
|---|---|---|
| Italy | HBV, HCV treatment adjuvant; cancer immune adjuvant | Zadaxin |
| China | HBV, HCV; cancer chemotherapy adjuvant | Zadaxin; generic versions |
| Philippines | Hepatitis B/C; immune modulation | Zadaxin |
| 35+ other countries | Hepatitis B/C; immune adjuvant | Zadaxin and generics |
| USA / EU | Not approved (never sought FDA/EMA approval) | N/A |
| India | Available via import; not CDSCO approved | Import license required |
Cancer Support Applications
Several Italian researchers have conducted RCTs using TA-1 as an adjuvant to chemotherapy:
- Non-small cell lung cancer (NSCLC): Multiple Italian RCTs show TA-1 as adjuvant to cisplatin-based chemotherapy improved immune function parameters and modestly improved overall survival in some studies
- Hepatocellular carcinoma: Italian trials show TA-1 + TACE (transarterial chemoembolization) improved immune parameters vs TACE alone
- The mechanism: chemotherapy causes profound immune suppression; TA-1 may partially preserve immune function during treatment, maintaining anti-tumor surveillance capacity
COVID-19 and Infectious Disease Context
TA-1 was used in several observational and small RCT studies during the COVID-19 pandemic in China and Italy, based on its established immune-modulating properties. Some studies reported improved outcomes, but this evidence is limited in quality and cannot be considered definitive.
The broader implication for longevity in the Indian context: TA-1's immune-enhancing effects for chronic viral infections (hepatitis B affects 40+ million Indians) and vaccine response optimization represent potentially important applications beyond the Western biohacking framing.
Dosing Protocol
- Standard therapeutic dose: 1.6 mg subcutaneously twice weekly for hepatitis treatment
- Prophylactic longevity use: Varies widely — some practitioners use 1.6 mg twice monthly for immune maintenance; no validated protocol
- Cancer adjuvant: 1.6 mg twice weekly during and after chemotherapy cycles
- Duration: 6 months for hepatitis treatment; ongoing for longevity use (no validated endpoint)
Zadaxin (branded TA-1) is available in India via import and can be obtained through specialty pharmacies under physician supervision. Generic TA-1 versions are also available as research peptides. Given India's high hepatitis B burden, there is more clinical rationale for TA-1 use here than in most Western markets.
Frequently Asked Questions
Is Thymosin Alpha-1 approved for use in India?
Thymosin Alpha-1 (Zadaxin) is approved in Italy, China, Philippines, and 35+ countries for hepatitis B/C and immune adjuvant use. It is not approved by CDSCO in India for standard clinical use, but is available via import license for specific applications and sold as a research peptide.
What does Thymosin Alpha-1 do for immunity?
TA-1 promotes maturation of dendritic cells, drives T-cell differentiation toward Th1 (cellular immunity), activates NK cells, and upregulates IL-2 and IFN-gamma. It also helps normalize excessive Th2 responses. The net effect is improved adaptive immune competence — particularly cellular immunity which declines most with age.
Thymosin Alpha-1 for cancer support — what does the evidence show?
Several Italian RCTs in lung cancer and hepatocellular carcinoma patients show TA-1 used as adjuvant to chemotherapy maintains immune function better than chemotherapy alone, with some improvements in response rates and overall survival. The evidence is modest but from controlled trials — not just anecdote.
Thymosin Alpha-1 vs other immune peptides — comparison?
TA-1 is the most clinically developed immune peptide with the most robust human evidence and international approvals. LL-37 is more of an innate immunity antimicrobial peptide. MOTS-c affects metabolism with secondary immune effects. TA-1 uniquely addresses the adaptive immune decline (thymic involution) most relevant to aging.